'Renal Pharma "- the path to a global and comprehensive treatment of end-stage renal failure

Fresenius Medical Care is now complementing its leading dialysis technologies, products and services with renal pharmaceuticals to achieve improved therapeutic outcomes in dialysis patients. The initial portfolio of dialysis-related drugs comprises phosphate binders, potassium binders, as well as a novel drug for anaemia management.
Further expansion of the dialysis-related drug portfolio will bring additional drugs and new formulations as well as drug/device combinations for integrated drug application with dialysis machines.

We also recommend viewing the website http://www.fmc-renalpharma.com/